At Regeneron we make it our business every day to bring innovative thinking to the challenge of discovering and developing new medicines. Our pursuit has one singular intent – to improve therapeutic outcomes for patients.
Our first approved product, ARCALYST® (rilonacept), an anti-inflammatory agent, has been available to patients in the U.S. since 2008.In late 2011, we launched EYLEA® (aflibercept) Injection, also known in the scientific literature as VEGF Trap-Eye and Intravitreal Aflibercept Injection.more
EYLEA® (aflibercept) Injection and ARCALYST® (rilonacept)more
At Regeneron, we are committed to a better future. This promise is at the core of our mission to discover and develop new medicines, which allows us to deliver greater value to our patients, employees and communities.more
Regeneron was founded by physician scientists, and today, more than 20 years later, strong science remains at the heart of our capabilities and culture.
Through our original research we have discovered novel drug targets such as angiopoietins and neurotrophins, and we have developed product candidates to these targets as well as to others that have been validated by academic researchers or other pharmaceutical companies.We have pursued both novel and validated targets because we believe this is a strategy that balances risk and reward.more
Senior Financial Analyst
Every career path is different. That’s why we help you design your own. We’ll provide the training, coaching and experiences that allow you to build relationships and take advantage of career opportunities.
Director Clinical Sciences Translational Medicine
Our drug development programs are propelled by the desire to address unmet medical needs, and all our work is done with the utmost integrity.
Quality Control Analyst III
Regeneron is a place where new ideas are welcome. The environment fosters growth and progress that allows us to produce a product that meets the highest quality standards.